177 related articles for article (PubMed ID: 18617442)
1. Current opinions on the role of pathogen reduction technology in improving the viral safety of blood and derivatives.
Seghatchian J
Transfus Apher Sci; 2008 Aug; 39(1):49-50. PubMed ID: 18617442
[No Abstract] [Full Text] [Related]
2. The six questions of pathogen reduction technology: an overview of current opinions.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2008 Aug; 39(1):51-7. PubMed ID: 18614401
[TBL] [Abstract][Full Text] [Related]
3. Pathogen reduction technology.
Rock G
Transfus Apher Sci; 2008 Aug; 39(1):1. PubMed ID: 18619904
[No Abstract] [Full Text] [Related]
4. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.
Svae TE; Neisser-Svae A; Bailey A; Reichl H; Biesert L; Schmidt T; Heger A; Römisch J
Transfus Apher Sci; 2008 Aug; 39(1):59-67. PubMed ID: 18619902
[TBL] [Abstract][Full Text] [Related]
5. Pathogen reduction of blood components.
Solheim BG
Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
[TBL] [Abstract][Full Text] [Related]
6. Update on pathogen reduction technology for therapeutic plasma: an overview.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
[TBL] [Abstract][Full Text] [Related]
7. Skin disinfection and bacterial contamination of blood components: be simple.
Bueno JL
Transfusion; 2010 Jan; 50(1):5-8. PubMed ID: 20233345
[No Abstract] [Full Text] [Related]
8. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
Klein HG; Glynn SA; Ness PM; Blajchman MA;
Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
[TBL] [Abstract][Full Text] [Related]
9. Pathogen reduction technique for fresh-frozen plasma, cryoprecipitate, and plasma fraction minipools prepared in disposable processing bag systems.
Burnouf T; Radosevich M; El-Ekiaby M; Goubran H
Transfusion; 2011 Feb; 51(2):446-7; author reply 447-8. PubMed ID: 21309785
[No Abstract] [Full Text] [Related]
10. Bacterial contamination of cellular blood components: risks, sources and control.
Blajchman MA
Vox Sang; 2004 Jul; 87 Suppl1():98-103. PubMed ID: 15200616
[No Abstract] [Full Text] [Related]
11. Current trends in blood component therapy: the evolution of a safer, more effective product.
Baranowski L
J Intraven Nurs; 1992; 15(3):136-51. PubMed ID: 1608013
[TBL] [Abstract][Full Text] [Related]
12. International forum on 'Perioperative blood salvage': a Spanish contribution.
Muñoz M; Gómez-Luque A; Ramírez G;
Vox Sang; 2007 Jan; 92(1):90. PubMed ID: 17181596
[No Abstract] [Full Text] [Related]
13. Pathogen inactivation: emerging indications.
Kleinman S
Curr Opin Hematol; 2015 Nov; 22(6):547-53. PubMed ID: 26390164
[TBL] [Abstract][Full Text] [Related]
14. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light.
Cardo LJ; Salata J; Mendez J; Reddy H; Goodrich R
Transfus Apher Sci; 2007 Oct; 37(2):131-7. PubMed ID: 17950672
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of microbial contaminants of blood components.
AuBuchon JP; Dodd RY
Clin Lab Med; 1992 Dec; 12(4):787-803. PubMed ID: 1286565
[TBL] [Abstract][Full Text] [Related]
16. [Pathogen inactivation in labile blood products: transfusion safety and economic impact].
Cazenave JP
Bull Acad Natl Med; 2006 Jan; 190(1):169-85; discussion 186-8. PubMed ID: 16878453
[TBL] [Abstract][Full Text] [Related]
17. Pathogen reduction technologies: what are the concerns?
AuBuchon JP
Vox Sang; 2004 Jul; 87 Suppl 2():84-9. PubMed ID: 15209887
[No Abstract] [Full Text] [Related]
18. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
[TBL] [Abstract][Full Text] [Related]
19. [Reducing the infectious risk of labile blood products].
Noël L
Presse Med; 1997 Apr; 26(14):685-90. PubMed ID: 9180891
[No Abstract] [Full Text] [Related]
20. Blood component therapy.
Fasano R; Luban NL
Pediatr Clin North Am; 2008 Apr; 55(2):421-45, ix. PubMed ID: 18381094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
